Intervacc Investor Relations Material
Latest events
Q3 2024
Intervacc
Q1 2025
14 May, 2025
Q4 2024
13 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Intervacc
Access all reports
Intervacc AB, a biotechnology company, engages in the research and development of veterinary vaccines using recombinant proteins for animal health. The company offers Canvax, a vaccine for bovine viral diarrhea; and Fervac B, a vaccine for feline viral rhinotracheitis, calicivirus, and panleukopenia. It also provides a range of potential prevention vaccines to veterinarians, including vaccines to control rabies. Intervacc is based in Hägersten, Sweden.
Latest articles
)
MSCI: Indexing the World
The story of how MSCI has become the backbone of global finance through its indexes, powering decision-making across trillions in assets.
30 May 2025
)
A Purpose-Built AI Chat for Finance and IR Professionals
Quartr Pro's new AI chat lets IR and finance professionals ask anything across 13,000+ public companies and get instant answers.
27 May 2025
)
Costco Wholesale: The Model of Scalable Simplicity
Costco's rise from warehouse club to retail giant is built on low prices, scale efficiency, and a model designed for lasting customer value.
26 May 2025
Ticker symbol
IVACC
Country
🇸🇪 Sweden